Show simple item record

dc.contributor.authorJha, R.M.
dc.contributor.authorBell, J.
dc.contributor.authorSimard, J.M.
dc.date.accessioned2020-02-04T17:04:33Z
dc.date.available2020-02-04T17:04:33Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85077855834&doi=10.3390%2fijms21020409&partnerID=40&md5=3cadbb03b34dda71dd594f2ad5cc5ed0
dc.identifier.urihttp://hdl.handle.net/10713/11677
dc.description.abstractCerebral edema and contusion expansion are major determinants of morbidity and mortality after TBI. Current treatment options are reactive, suboptimal and associated with significant side effects. First discovered in models of focal cerebral ischemia, there is increasing evidence that the sulfonylurea receptor 1 (SUR1)-Transient receptor potential melastatin 4 (TRPM4) channel plays a key role in these critical secondary injury processes after TBI. Targeted SUR1-TRPM4 channel inhibition with glibenclamide has been shown to reduce edema and progression of hemorrhage, particularly in preclinical models of contusional TBI. Results from small clinical trials evaluating glibenclamide in TBI have been encouraging. A Phase-2 study evaluating the safety and efficacy of intravenous glibenclamide (BIIB093) in brain contusion is actively enrolling subjects. In this comprehensive narrative review, we summarize the molecular basis of SUR1-TRPM4 related pathology and discuss TBI-specific expression patterns, biomarker potential, genetic variation, preclinical experiments, and clinical studies evaluating the utility of treatment with glibenclamide in this disease.en_US
dc.description.urihttps://doi.org/10.3390/ijms21020409en_US
dc.language.isoen_USen_US
dc.publisherMDPIen_US
dc.relation.ispartofInternational journal of molecular sciences
dc.subjectASTRALen_US
dc.subjectcerebral edemaen_US
dc.subjectcontusion expansionen_US
dc.subjectglibenclamideen_US
dc.subjectglyburideen_US
dc.subjectSUR1 (Sulfonylurea receptor 1)en_US
dc.subjectTBI (traumatic brain injury)en_US
dc.subjectTRPM4 (transient receptor potential melastatin 4)en_US
dc.titleRole of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidenceen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/ijms21020409
dc.identifier.pmid31936452


This item appears in the following Collection(s)

Show simple item record